Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.39 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.39 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258625 | 0.82 | MAPT (0.45) | MAPTPOLBATMMEN1LMNA | |
| SCHEMBL3924246 | 0.80 | NR1I2 (0.43) | — | |
| SCHEMBL6732577 | 0.80 | MAPT (0.45) | MAPTPOLBATMMEN1LMNA | |
| SCHEMBL5309142 | 0.77 | HPGD (0.44) | POLBLMNA | |
| SCHEMBL10342776 | 0.75 | MAPT (0.57) | MAPTPOLBATMMEN1LMNA | |
| SCHEMBL29811344 | 0.75 | MAPT (0.57) | MAPTPOLBATMMEN1LMNA | |
| SCHEMBL19086567 | 0.73 | SIGMAR1 (0.36) | ACHEMAPTLMNAKMT2ASIGMAR1 | |
| SCHEMBL11859025 | 0.71 | IRAK4 (0.39) | ACHEMAPTPOLBATMMEN1 | |
| SCHEMBL17434366 | 0.70 | PDE5A (0.51) | MAPTPOLBATMMEN1LMNA | |
| SCHEMBL26925116 | 0.69 | MEN1 (0.60) | MAPTPOLBMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | ACHE 1450/4885MAPT 4204/4885POLB 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.